CHARM Therapeutics Overview
- Year Founded
-
2021
- Status
-
Private
- Employees
-
29
- Latest Deal Type
-
Series B
- Latest Deal Amount
-
$80M
- Investors
-
16
CHARM Therapeutics General Information
Description
Developer of AI-designed precision oncology therapeutics designed to overcome drug resistance and improve treatment outcomes for patients with acute myeloid leukemia. The company's drug discovery program uses its proprietary deep-learning platform to model protein-ligand interactions and design structurally optimized small-molecule inhibitors, with its lead candidate, CHM-029, engineered to retain potency against known menin resistance mutations associated with acute myeloid leukemia (AML), enabling clinicians to develop targeted cancer therapies to address treatment resistance and support more durable responses.
Contact Information
Website
www.charmtx.comCorporate Office
- The Stanley Building
- 7 Pancras Square
- London N1C 4AG
- England, United Kingdom
Corporate Office
- The Stanley Building
- 7 Pancras Square
- London N1C 4AG
- England, United Kingdom
CHARM Therapeutics Timeline
CHARM Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Early Stage VC (Series B) | 02-Sep-2025 | $80M | Completed | Generating Revenue | ||
| 2. Early Stage VC | 14-Apr-2023 | Completed | Generating Revenue | |||
| 1. Early Stage VC (Series A) | 18-Apr-2022 | $50M | $50M | Completed | Generating Revenue |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
CHARM Therapeutics Comparisons
Industry
Financing
Details
CHARM Therapeutics Competitors (10)
One of CHARM Therapeutics’s 10 competitors is Oxford Biotherapeutics, a Private Equity-Backed company based in Oxford, United Kingdom.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Oxford Biotherapeutics | Private Equity-Backed | Oxford, United Kingdom | ||||
| Carrick Therapeutics | Venture Capital-Backed | Boston, MA | ||||
| Mestag Therapeutics | Venture Capital-Backed | Cambridge, United Kingdom | ||||
| Strata Oncology | Venture Capital-Backed | Ann Arbor, MI | ||||
| PreciseDx | Venture Capital-Backed | New York, NY |
CHARM Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
CHARM Therapeutics Patents
CHARM Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20260167647-A1 | Therapeutic agents | Pending | 16-Dec-2024 | ||
| WO-2026131815-A1 | Therapeutic agents | Pending | 16-Dec-2024 | ||
| US-12211588-B1 | Methods and systems for using deep learning to predict protein-ligand complex structures in protein folding and protein-ligand co-folding | Active | 30-Sep-2022 | G16B15/30 |
CHARM Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
CHARM Therapeutics Investors (16)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| New Enterprise Associates | Venture Capital | Minority | ||
| NVIDIA | Corporation | Minority | ||
| SR One | Corporate Venture Capital | Minority | ||
| Bristol-Myers Squibb | Corporation | Minority | ||
| NVentures (Santa Clara) | Corporate Venture Capital | Minority |
CHARM Therapeutics FAQs
-
When was CHARM Therapeutics founded?
CHARM Therapeutics was founded in 2021.
-
Where is CHARM Therapeutics headquartered?
CHARM Therapeutics is headquartered in London, United Kingdom.
-
What is the size of CHARM Therapeutics?
CHARM Therapeutics has 29 total employees.
-
What industry is CHARM Therapeutics in?
CHARM Therapeutics’s primary industry is Drug Discovery.
-
Is CHARM Therapeutics a private or public company?
CHARM Therapeutics is a Private company.
-
What is CHARM Therapeutics’s current revenue?
The current revenue for CHARM Therapeutics is .
-
How much funding has CHARM Therapeutics raised over time?
CHARM Therapeutics has raised $150M.
-
Who are CHARM Therapeutics’s investors?
New Enterprise Associates, NVIDIA, SR One, Bristol-Myers Squibb, and NVentures (Santa Clara) are 5 of 16 investors who have invested in CHARM Therapeutics.
-
Who are CHARM Therapeutics’s competitors?
Oxford Biotherapeutics, Carrick Therapeutics, Mestag Therapeutics, Strata Oncology, and PreciseDx are some of the 10 competitors of CHARM Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
